A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

NCT07172867 on ClinicalTrials.gov · last registry update 2026-02-25

Withdrawn before anyone was enrolled. The sponsor logged completion for 23 January 2026. Primary outcome, as filed: Assess glycemic control using HbA1c (%). semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Halia Therapeutics, Inc.
Sponsor type: Industry
Enrollment: 0
Started: 2026-01-06
Primary completion: 2026-01-23 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Assess glycemic control using HbA1c (%)

Conditions studied

Diabetes Mellitus, Type 2 · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.